Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies.
- 1 December 1994
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 38 (6) , 513-519
- https://doi.org/10.1111/j.1365-2125.1994.tb04392.x
Abstract
1. Pravastatin, a 3‐hydroxy‐3‐methylglutaryl coenzyme‐A (HMG‐CoA) inhibitor, is a highly selective inhibitor of hepatic cholesterol synthesis. We studied the in vivo and in vitro effects of pravastatin on macrophage cholesterol metabolism. 2. The effects of incubating pravastatin with human monocyte derived macrophages (HMDM), mouse peritoneal macrophages (MPM) and a J‐774 A.1 macrophage‐like cell line, on macrophage cholesterol synthesis, cellular degradation of native low density lipoprotein (LDL) and modified LDL, cholesterol efflux from these cells and the cholesterol esterification rate were determined. 3. Pravastatin was administered either as one 40 mg dose or 40 mg daily for 8 weeks to normocholesterolaemic and hypercholesterolaemic individuals. The effects on cholesterol synthesis and degradation in monocytes derived from these subjects were studied. 4. In vitro, pravastatin resulted in a dose‐dependent inhibition of macrophage cholesterol synthesis. Cellular degradation of native LDL increased by 119% in the presence of 0.1 mg ml‐1 pravastatin. Degradation of both acetyl LDL and oxidized LDL was unaffected. Small concentrations of pravastatin (up to 0.19 micrograms ml‐1) increased the cellular cholesterol esterification rate after incubation with LDL, but higher concentrations resulted in an inhibition of the esterification. 5. Single dose pravastatin administration caused a reduction in cholesterol synthesis by the subjects own HMDM by 62% and 47% in normocholesterolaemic and hypercholesterolaemic individuals, respectively. Chronic administration resulted in a 55% inhibition of cholesterol synthesis and a 57% increase in LDL degradation. 6. The results indicate that the selective uptake of pravastatin shown for hepatocytes can be extended to macrophages.(ABSTRACT TRUNCATED AT 250 WORDS)Keywords
This publication has 28 references indexed in Scilit:
- Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanismsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1991
- Dual Effect of Lovastatin and Simvastatin on LDL-Macrophage Interactioncclm, 1991
- Vastatins inhibit cholesterol ester accumulation in human monocyte-derived macrophages.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1991
- Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductaseBiochemical and Biophysical Research Communications, 1990
- Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitorBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1990
- Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivoBiochemical and Biophysical Research Communications, 1989
- Platelet-Modified Low Density Lipoprotein Induces Macrophage Cholesterol Accumulation and Platelet Activationcclm, 1989
- CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal speciesBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1986
- Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patientsBiochemical Medicine, 1983
- The metabolism of very low density lipoprotein proteins I. Preliminary in vitro and in vivo observationsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1972